RxDoctor Payments Data

Joseph Defoto, MD

Family Medicine · Los Angeles, CANPI 1033149711

Payments from drug & device makers

$13,266in general payments, 2019–2025

Across 717 payments — averaging $18.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$6K
  • Gilead$4K
  • Johnson & Johnson$901
  • Merck$525
  • EMD Serono, Inc.$435
  • Napo Pharmaceuticals Inc$346
  • plus $2K from 18 others

What the payments were for

  • Speaking & faculty fees$1451%
  • Food & beverage$13,06298%
  • Education$600%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$13,266 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$57,561
Medicare patients
103
Services billed
1,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala212$871,464
SerostimSomatropin37$717,100
SymtuzaDarunavir/Cob/Emtri/Tenof Alaf76$340,446
DescovyEmtricitabine/Tenofov Alafenam91$230,776
TivicayDolutegravir Sodium72$228,248
JulucaDolutegravir/Rilpivirine31$103,946
DovatoDolutegravir Sodium/Lamivudine20$57,685
TriumeqAbacavir/Dolutegravir/Lamivudi11$40,564
OdefseyEmtricitab/Rilpiviri/Tenof Ala11$39,216
OzempicSemaglutide24$28,201
IsentressRaltegravir Potassium12$23,398
Maraviroc26$20,913
Nevirapine ErNevirapine53$13,312
Repatha SureclickEvolocumab20$11,041
XareltoRivaroxaban11$9,906

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy$3,967$1,102,240303 claims
EMD Serono, Inc.Serostim$435$717,10037 claims
Viiv Healthcare CompanyTivicay, Juluca, Dovato, Triumeq$5,567$430,443134 claims
Janssen Products, LPSymtuza$31$340,44676 claims
Novo NordiskOzempic$22$28,20124 claims
MerckIsentress$525$23,39812 claims
Johnson & JohnsonXarelto$901$9,90611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →